Seminars in Hematology
Volume 37, Issue 3 , Pages 261-266 , July 2000

Fc receptor blockade and immune thrombocytopenic purpura

  • James B Bussel

      Affiliations

    • Corresponding Author InformationAddress reprint requests to James B. Bussel, MD, Division of Pediatrics, New York Hospital, 525 E 68th St, Payson 6, New York, NY 10021.

References 

  1. Becker T, Kuenzlen E, Salama A, et al.  Treatment of childhood idiopathic thrombocytopenic purpura with Rhesus antibodies (anti-D). Eur J Pediatr. 1986;45:166–169
  2. Berchtold P, Dale GL, Tani P, et al.  Inhibition of autoantibody binding to platelet glycoprotein IIb/IIIa by anti-idiotypic antibodies in intravenous gammaglobulin. Blood. 1989;74:2414–2417
  3. Blanchette V, Imbach P, Andrew M, et al.  Randomized trial of immunoglobulin G, intravenous anti-D and oral prednisone in acute immune thrombocytopenic purpura. Lancet. 1994;344:703–707
  4. Boros P, Muryoi T, Spiera H, et al.  Autoantibodies directed against different classes of Fc gamma R are found in sera of autoimmune patients. J Immunol. 1993;150:2018–2024
  5. Boughton BJ. Anti-D IG for treatment of immune thrombo-cytopenic purpura. Blood. 1991;78:2157; (letter)
  6. Burdach SEG, Guersen RG. Mechanisms of intravenous immunoglobulin treatment in childhood acute idiopathic thrombocytopenic purpura. Comparison of F(ab)2 versus Fc containing IgG. Pediatr Res. 1985;19:259A; (abstr)
  7. Bussel JB, Cines D. Immune thrombocytopenic purpura, neonatal alloimmune thrombocytopenic and posttransfusion purpura. In:  Hoffman R,  Benz EJ,  Shattil SJ editor. Hematology: Basic Principles and Practice. New York, NY: Churchill Livingstone; 1999;p. 2096–2114
  8. Bussel JB, Graziano JN, Kimberly RP, et al.  Anti-D IG for treatment of immune thrombocytopenic purpura. Blood. 1991;78:2157–2158 (letter)
  9. Bussel JB, Graziano JN, Kimberly RP, et al.  Intravenous anti-D treatment of immune thrombocytopenic purpura: Analysis of efficacy, toxicity, and mechanism of effect. Blood. 1988;72:121–127
  10. Bussel JB, Hilgartner MW. The use and mechanism of action of intravenous immunoglobulin in the treatment of immune haematologic disease. Br J Haematol. 1984;56:1–7
  11. Bussel JB, Kimberly R, Clarkson S, et al.  Infusion of a monoclonal anti-FcR III in patients with refractory ITP. Neoadjuvant Chemother. 1990;169:883–890
  12. Bussel JB, Kimberly RP, Inman RD, et al.  Intravenous gammaglobulin treatment of chronic idiopathic thrombocy-topenic purpura. Blood. 1983;62:480–486
  13. Bussel JB, Novoa M, Shine E, et al: In patients with ITP, does 75 μg/kg of IV anti-D increase the platelet count faster than 50 μg/kg? Br J Hematol (in press)
  14. Carroll MC. The role of complement and complement receptors in induction and regulation of immunity. Ann Rev Immunol. 1998;16:545–568
  15. Clarkson SB, Bussel JB, Kimberly RP, et al.  Treatment of refractory immune thrombocytopenic purpura with an anti-Fc gamma-receptor antibody. N Engl J Med. 1986;314:1236–1239
  16. Clarkson SB, Kimberly RP, Bussel JB, et al: Blockade of immune complex clearance by a monoclonal antibody. Br J Hematol (in press)
  17. Debre M, Bonnet MC, Fridman WH, et al.  Infusion of Fc gamma fragments for treatment of children with acute immune thrombocytopenic purpura. Lancet. 1993;342:945–949
  18. Ericson SG, Coleman KD, Wardwell K, et al.  Monoclonal antibody 197 (anti-Fc gamma RI) infusion in a patient with immune thrombocytopenia purpura (ITP) results in down-modulation of Fc gamma RI on circulating monocytes. Br J Haematol. 1996;92:718–724
  19. Fehr J, Hofmann V, Kappeler U. Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high-dose intravenous gammaglobulin. N Engl J Med. 1982;306:1254–1256
  20. Fleit HB, Wright SD, Unkeless JC. Human neutrophil Fc receptor distribution and function. In: Proc Natl Acad Sci USA. 79:1982;p. 3275–3280
  21. George JN, Woolf SH, Raskob GE, et al.  Idiopathic thrombocytopenic purpura: A practice guideline developed by explicit methods for the American Society of Hematology. Blood. 1996;88:3–41
  22. Godeau B, Oksenhendler E, Brossard Y. Treatment of chronic autoimmune thrombocytopenic purpura with monoclonal anti-D. Transfusion. 1996;36:328–330
  23. Gordon JM, Cohen P, Finlayson JS. Levels of anti-A and anti-B in commercial immuneglobulins. Transfusion. 1980;20:17–23
  24. Handin RI, Stossel TP. Phagocytosis of antibody-coated platelets by human granulocytes. N Engl J Med. 1974;290:989–993
  25. Harrington WJ, Minnich V, Hollingsworth JW, et al.  Demonstration of a thrombocytopenic factor in the blood of patients with thrombocytopenic purpura. J Lab Clin Med. 1951;38:1–8
  26. Heyman B. Complement and Fc-receptors in regulation of the antibody response. Immunol Lett. 1996;54:195–199
  27. Imbach P, Barandun S, Baumgartner C, et al.  High-dose intravenous gammaglobulin therapy of refractory, in particular idiopathic thrombocytopenia in childhood. Helv Paediatr Acta. 1981;36:81–86
  28. Imbach P, Barandun S, díApuzzo V, et al.  High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet. 1981;1:1228–1231
  29. Kelton JG, Singer J, Rodger C, et al.  The concentration of IgG in the serum is a major determinant of Fc-dependent reticuloendothelial function. Blood. 1985;66:490–495
  30. Kimbely RP, Salmon JE, Bussel JB, et al.  Modulation of mononuclear phagocyte function by intravenous gammaglobulin. J Immunol. 1984;132:745–750
  31. Kumpel BM, Goodrick ML, Pamphilon DH, et al.  Human Rh D monoclonal antibodies (BRAD-3 and BRAD-5) cause accelerated clearance of Rh D+ red blood cells and suppression of Rh D immunization in Rh D-volunteers. Blood. 1995;86:1701–1709
  32. Nicol T, Bilbey DLJ. The effect of various steroids on the phagocytic activity of the reticuloendothelial system, in Heler JH (ed): Reticuloendothelial Structure and Function. Ronald. In: 1960;p. 301–310
  33. Oksenhendler E, Bierling P, Brossard Y, et al.  Anti-RH immunoglobulin therapy for human immunodeficiency virus-related immune thrombocytopenic purpura. Blood. 1998;71:1499–1502
  34. Ravetch JV. Fc receptors. Curr Opin Immunol. 1997;9:121–125
  35. Salama A, Kiefel V, Amberg R, et al.  Treatment of autoimmune thrombocytopenic purpura with Rhesus antibodies [anti-Rh0(D)]. Blut. 1984;49:29–35
  36. Salama A, Kiefel V, Mueller-Eckhardt C. Effect of IgG anti-Rho(D) in adult patients with chronic autoimmune thrombocytopenia. Am J Hematol. 1986;22:241–250
  37. Salama A, Mueller-Eckhardt C, Kiefel V. Effect of intravenous immunoglobulin in immune thrombocytopenia. Lancet. 1983;2:193–195
  38. Sandor M, Lynch RG. The biology and the pathology of Fc receptors. J Clin Immunol. 1993;13:237–246
  39. Scaradavou A, Woo B, Woloski BMR, et al.  Intravenous anti-D treatment of immune thrombocytopenic purpura: Experience in 272 patients. Blood. 1997;89:2689–2700
  40. Shulman NR, Weinrach RS, Libre EP, et al.  The role of the reticuloendothelial system in the pathogenesis of idiopathic thrombocytopenic purpura. Trans Assoc Am Phys. 1965;78:374–386
  41. Tankersley D, Preston S, Finlayson JS. Immunoglobulin G dimer: An idiotype-anti-idiotype complex. Mol Immunol. 1998;25:41–48
  42. Tovo PA, Miniero R, Fiandino G, et al.  Fc-depleted vs. intact intravenous immunoglobulin in chronic ITP. J Pediatr. 1984;105:676–677

PII: S0037-1963(00)90104-5

Seminars in Hematology
Volume 37, Issue 3 , Pages 261-266 , July 2000

Article Tools